Trial Profile
Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Apr 2023
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Pyoderma gangrenosum
- Focus Therapeutic Use
- 19 Mar 2020 Status changed from active, no longer recruiting to completed.
- 17 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 30 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2020.